TICKERNERD
Menu
CMNDCMNDHealthcare · Biotechnology

CMND Stock Forecast: Clearmind Medicine, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$6.00
+1.01% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 22 Oct 2026 — in the weakest quartile.

Market cap
$3.0M
Ticker Nerd rank
6/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.2M
Net income−$907K
Free cash flow−$2.7M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.5%
1M
−4.0%
YTD
−95.9%
1Y
−99.8%
From 52W high
−99.8%
From 52W low
+4.9%
$6
$3,232
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CMND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clearmind Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
6/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Quality
36
Growth
25
Revisions
25
Accruals
21
Momentum
16
Volatility
15
Value
5
Issuance
4

Size (97): Smaller than most of the companies we track.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CMND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CMND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$1,000$2,000$3,000Jan 26Apr 26Jul 26Oct 26CMND

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CMND appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

CMND vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Clearmind Medicine, Inc. returned −99.8% against +15.6% for the S&P 500, dividends included.

CMND vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26CMNDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CMND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Clearmind Medicine, Inc. (CMND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 89% of US stocks

EV / EBITDA
1.3×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−107.0%

Higher than 12% of US stocks

Return on assets
−53.1%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Clearmind Medicine, Inc. (CMND) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Clearmind Medicine, Inc. has a market value of $3.0M and an enterprise value of −$11.6M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$7.5M.

  • Free cash flow in the twelve months to 31 July 2026: −$7.8M.

  • Shares outstanding: 1.5M.

  • Trailing P/E: 0.2×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Clearmind Medicine, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

CMND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CMNDClearmind Medicine, Inc.$3.0M6
SXTP60 Degrees Pharmaceuticals, Inc.$3.1M41
GRIGRI Bio, Inc.$3.1M34
APVOAptevo Therapeutics, Inc.$2.9M30
EOCNEocene Ltd.$3.2M21
PPCBPropanc Biopharma, Inc.$2.8M52
MBIOMustang Bio, Inc.$2.8M14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Clearmind Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CMND news & analysis

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

GlobeNewsWire · 8 Oct 2026positive

Clearmind announced publication in Japan of a patent application covering 3-MMC-based compositions and methods to prevent, treat, or reduce dyskinesia symptoms, including use in combination with PEA.

Why it matters — The publication adds a Japan-focused patent application related to a potential dyskinesia treatment to Clearmind’s disclosed intellectual-property activity.

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

GlobeNewsWire · 7 Oct 2026positive

Clearmind said it submitted recommendations to the FDA as part of its dialogue with the U.S. federal government on psychedelic therapies. The company called for consideration of new regulatory pathways and cost savings for non-hallucinogenic neuroplastogens for alcohol use disorder.

Why it matters — The recommendations relate to potential regulatory approaches for therapies in an area relevant to Clearmind’s work.

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

TheNewswire · 23 Sept 2026positive

NeuroThera Labs highlighted the expansion of its U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine. The patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine, and ibogaine for potential therapeutic applications, including mental health disorders such as depression and PTSD, as well as substance use disorders.

Why it matters — This news showcases progress in Clearmind's collaborative intellectual property development, potentially strengthening its position in the psychedelic-based therapeutic space.

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

GlobeNewsWire · 23 Sept 2026positive

Clearmind Medicine enhanced its U.S. intellectual property presence by publishing three patent applications covering combinations of LSD, ketamine, and ibogaine. The applications address potential therapeutic uses for mental health disorders such as depression and PTSD, as well as substance use disorders.

Why it matters — A CMND watcher would care because the expanded patent portfolio could strengthen the company's intellectual property position in its pipeline of psychedelic-based therapeutics for mental health and substance use disorders.

Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio

TheNewswire · 17 Sept 2026neutral

StickIt Technologies issued a corporate update outlining changes to its board of directors and executive management, recent financial transactions including loan acquisitions and private placements, and developments across its international intellectual property portfolio of proprietary cannabinoid and plant extract delivery technologies.

Why it matters — As a company developing and patenting cannabinoid and plant extract delivery technologies, StickIt's leadership, financing, and IP developments are relevant context for those tracking competitors in the cannabinoid delivery space relevant to Clearmind Medicine.

FAQ

Frequently asked questions about CMND stock

How does Ticker Nerd's model rank CMND?

As at 22 Oct 2026, Clearmind Medicine, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the CMND stock forecast for 2030?

No analyst covering Clearmind Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMND are extrapolating price history, which says nothing about the business.

How has CMND stock performed over the past year?

Clearmind Medicine, Inc. returned -99.8% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clearmind Medicine, Inc. do?

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions.

What is the latest news on CMND?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder". Clearmind announced publication in Japan of a patent application covering 3-MMC-based compositions and methods to prevent, treat, or reduce dyskinesia symptoms, including use in combination with PEA.

Company

About Clearmind Medicine, Inc.

Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions. The company’s current work centers on researching and advancing treatments for alcohol use disorder and related behavioral health indications, using proprietary small-molecule drug candidates designed to target underlying neurobiological pathways. Clearmind Medicine also operates consumer-oriented and research-driven programs tied to its therapeutic platform, reflecting a broader approach that combines pharmaceutical development with adjacent product concepts. Based in Vancouver, Canada, with active research and development activities in Israel, Clearmind Medicine participates in the life sciences market through a specialized pipeline aimed at regulated medicine development. Its common shares are used by investors to gain exposure to the company’s ongoing biotech research, clinical programs, and intellectual property-driven business model.

Canada · https://www.clearmindmedicine.com